The tweet was deleted by the author.
But we saved everything 🙂.
Agenus returned from several days in Chicago at ASCO2026 invigorated to advance immuno-oncology research for patients.
The company used the conference to network with IO experts, participate in scientific sessions, and renew ties within the oncology field. The event is considered a pivotal gathering for scientific exchange and collaboration among oncology professionals. Agenus stated it is now focused on translating insights from the conference into further developments for patient care.
View post on X Loading...
Earlier this year, Agenus reported a median overall survival of 16.6 months from its BOT plus BAL regimen in checkpoint-refractory melanoma patients, according to company data. The results were observed in a heavily treated patient population. Agenus continues to update the oncology community on its clinical progress.